Endoscope Sterilization Market: as revised Joint Commission 2024 HLD standards mandate real-time disinfection cycle tracking and FDA duodenoscope reprocessing guidance accelerates liquid chemical sterilant and automated endoscope reprocessor adoption at hospital endoscopy suites, peracetic acid-based liquid chemical sterilants gain market share over glutaraldehyde HLD chemistries by providing sporicidal activity at temperatures compatible with heat-sensitive flexible endoscope materials, so the growing conversion to single-use disposable endoscopes in bronchoscopy and urology applications reduces the reprocessing consumable addressable base while core GI endoscopy reprocessing volumes remain structurally secure from single-use conversion at current cost economics.

The global endoscope sterilization market size was USD 1.36 Billion in 2025 and is expected to register a revenue CAGR of 8.5% during the forecast period. Market revenue growth is driven by factors such as Joint Commission 2024 revised HLD standards mandating real-time disinfection cycle tracking and FDA duodenoscope reprocessing guidance creating compliance urgency for AER and validated sterilant adoption, the adoption of peracetic acid-based liquid chemical sterilant systems providing sporicidal efficacy at low temperatures compatible with flexible endoscope materials, and as well as competitive landscape restructuring through the HOYA 100% Wassenburg Medical acquisition and the SteelcoBelimed JV expanding integrated endoscope-plus-sterilization-equipment commercial offerings. The first driving factor is the revised Joint Commission 2024 infection prevention standards mandating real-time tracking of every high-level disinfection cycle including automated recording of chemical concentration, temperature, exposure time, and operator identity, requirements compelling investment in automated endoscope reprocessors with integrated cycle logging at facilities not yet equipped with digital documentation capability, combined with FDA guidance on duodenoscope reprocessing updated progressively from 2015 through 2024 recommending validated automated reprocessing with microbiological kill performance for high-risk patient populations. The second driving factor is the adoption of peracetic acid-based liquid chemical sterilant systems offering sporicidal efficacy at low temperatures compatible with heat-sensitive flexible endoscope materials that cannot withstand steam autoclaving, with Advanced Sterilization Products SYSTEM 1E and RELIANCE EPS using peracetic acid formulations providing sterilisation assurance for flexible endoscopes used in immunocompromised haematology and oncology patients where HLD alone may not provide sufficient infection control margin against Clostridioides difficile spores and other sporulating pathogens. The third driving factor is the HOYA 100% acquisition of Wassenburg Medical in November 2023 and the SteelcoBelimed JV finalised in June 2024, both creating integrated endoscope-plus-sterilization-equipment commercial platforms that allow hospital procurement committees to obtain validated scope-sterilization-system compatibility assurance and unified service responsibility from a single vendor, mirroring the Olympus ETD model that has been commercially effective for Olympus at hospital endoscopy department accounts globally. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way regulatory compliance mandates create non-discretionary capital and consumable expenditure that sustains sterilization product revenue independent of hospital discretionary spending cycles, which allows the endoscope sterilization market to maintain above-healthcare-spending-average growth rates even during periods of hospital capital constraint. Regulatory-driven demand works commercially because facilities that receive Joint Commission citations or FDA warning letters for inadequate endoscope reprocessing documentation face reputational and liability consequences that motivate rapid compliance investment regardless of annual capital budget cycles, converting the regulatory mandate into a committed procurement decision that bypasses normal procurement cycle timelines. As a result, demand and revenue share are concentrating around the sterilization system providers with the strongest validated performance documentation and the most established hospital sterile processing department service relationships, and the forecast tilts toward these compliance-positioning platforms rather than cost-competitor alternatives that cannot match the validated performance documentation of leading AER and liquid chemical sterilant providers. For instance, in June 2023, Olympus launched the ETD Endoscope Washer Disinfector in Basic and Premium versions using peracetic acid chemistry, one of several regulatory and commercial events that reshaped the competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the combined effect of Joint Commission 2024 revised infection prevention standards and FDA progressive duodenoscope reprocessing guidance, both creating non-discretionary compliance investment requirements for US hospital endoscopy suites that have not yet implemented digital cycle documentation and validated automated reprocessing. Regulatory-driven AER adoption works commercially because the Joint Commission 2024 mandate requires real-time automated tracking of every HLD cycle including chemical concentration, temperature, exposure time, and operator identity for each reprocessing cycle, requiring either new AER investment with integrated digital logging or HLD chemical monitoring hardware retrofits at facilities managing manual tracking workflows that cannot satisfy the real-time documentation standard. FDA guidance on duodenoscope reprocessing updated from 2015 through 2024 recommends microbiological culturing between uses, enhanced elevator channel brushing, and validated AER systems for high-risk patient populations, driving hospital procurement of validated automated reprocessing systems that provide documented microbiological kill performance against carbapenem-resistant Enterobacteriaceae. STERIS Healthcare segment, which includes automated endoscope reprocessing systems and HLD products, reported 14% revenue growth in Q4 fiscal 2024 per the company's earnings press release, with consumable revenue growing 14% and service revenue growing 9%, demonstrating the recurring commercial significance of HLD chemistry and service contracts associated with AER capital equipment installed bases. Custom Ultrasonics' September 2024 FDA manufacturing clearance restored System 83 Plus AER supply to US hospital endoscopy departments, and Olympus launched the ETD Endoscope Washer Disinfector in June 2023 with PAA-based chemistry and digital compliance documentation. These are some of the key factors driving revenue growth of the market.

The second driver is the progressive market share capture of peracetic acid-based liquid chemical sterilant systems from glutaraldehyde-based HLD chemistries, driven by the clinical requirement for sporicidal efficacy in flexible endoscope reprocessing at facilities treating immunocompromised patients where standard HLD against vegetative bacteria and mycobacteria does not provide sufficient infection control margin. Liquid chemical sterilization works commercially because high-level disinfection with glutaraldehyde or ortho-phthalaldehyde eliminates vegetative bacteria, mycobacteria, most viruses, and fungi but does not provide sporicidal activity sufficient to achieve sterilization, leaving a residual Clostridioides difficile spore and CRE contamination risk on flexible endoscope channels that peracetic acid sterilant systems at sporicidal concentrations can eliminate. Advanced Sterilization Products SYSTEM 1E and RELIANCE EPS liquid chemical sterilization systems using peracetic acid provide sporicidal efficacy at temperatures compatible with flexible endoscope materials, achieving sterilization assurance for scopes used in immunocompromised haematology and oncology patients. In July 2023, Olympus launched a low-temperature disinfection system using peracetic acid and glutaraldehyde-free solutions, reflecting industry shift toward non-aldehyde chemistries. WHO reported healthcare-associated infections affect approximately 7% of hospitalised patients in high-income countries annually, creating sustained institutional incentive for validated sterilisation chemistries minimising endoscope-mediated transmission of C. difficile, CRE, and priority healthcare pathogens. Iran-US sanctions disruption to glutaraldehyde and OPA chemical precursor supply chains has maintained elevated input costs for aldehyde HLD products through 2026, making the total cost comparison between aldehyde HLD and peracetic acid or plasma-based chemistries more favourable to non-aldehyde alternatives than pre-2022 pricing would have suggested. These are some of the key factors driving revenue growth of the market.

HOYA's Wassenburg acquisition is the other structural deal reshaping the endoscope sterilization competitive landscape. Pentax Medical's commercial value increases when HOYA can offer the endoscope and the validated reprocessing system from the same manufacturer with integrated compatibility assurance. That is the Olympus model, with Olympus endoscopes reprocessed in Olympus ETD systems, and HOYA is now positioned to compete on that integration argument with Pentax endoscopes and Wassenburg AERs.

The third driver is the competitive restructuring of the endoscope sterilization market through the SteelcoBelimed JV and HOYA-Wassenburg integration, both creating commercial platforms that can offer hospital procurement committees validated scope-sterilization-system combinations with unified service responsibility, intensifying competition for the European hospital CSSD equipment tender market that STERIS has dominated as the only North American company with comprehensive portfolio breadth across the complete CSSD equipment category. Competitive restructuring works commercially because European public hospital procurement frameworks typically require CSSD equipment including AERs, instrument washers, and steam sterilizers to be sourced from a single qualified vendor to simplify service responsibility, compliance documentation, and warranty management, a requirement that STERIS satisfies with its comprehensive portfolio but that has historically excluded European-headquartered specialist AER manufacturers without the full instrument washer and sterilizer product line. Metall Zug and Miele finalised the SteelcoBelimed joint venture in June 2024, combining Steelco's Italian washer-disinfector manufacturing platform and Belimed's Swiss sterilization engineering expertise to create a European CSSD platform capable of competing with STERIS on portfolio completeness in European public hospital tenders. HOYA completed the 100% Wassenburg Medical acquisition in November 2023, enabling HOYA Pentax Medical to offer hospital procurement committees a validated Pentax endoscope plus Wassenburg AER sterilization system commercial bundle. NHS England's GBP 4.1 billion endoscopy infrastructure programme is driving AER procurement at NHS trust endoscopy units, with Belimed posting 7.3% organic hospital-segment growth in Q3 2024 per commercial reporting reflecting European hospital endoscopy suite AER investment. These are some of the key factors driving revenue growth of the market.

However, the endoscope sterilization market faces adoption constraints from single-use endoscope conversion and high validated sterilant chemistry costs at cost-constrained hospital accounts. Because single-use endoscope adoption is growing at approximately 12.5% annually in bronchoscopy and ureteroscopy driven by Ambu reporting 15.4% organic Endoscopy Solutions growth in FY2024/25 and the FDA June 2025 clearance of the aScope 5 Cysto HD expanding into urology, each converted high-risk procedure scope department eliminates its per-procedure HLD chemistry consumption and reduces the endoscope inventory requiring validated reprocessing at those sites, creating a structural headwind for sterilant consumable revenue in the bronchoscopy and urology applications where clinical infection control evidence most strongly supports single-use conversion. High validated peracetic acid and hydrogen peroxide sterilant chemistry costs relative to glutaraldehyde-based HLD products constrain chemistry upgrade adoption at cost-constrained community hospitals and outpatient GI centres that cannot recover the premium sterilant cost premium through procedure reimbursement differentials, limiting liquid chemical sterilization adoption to higher-reimbursement hospital settings treating immunocompromised patient populations where the clinical case for sporicidal sterilant is most compelling. Regulatory divergence between FDA endoscope reprocessing guidance and ISO 15883 washer-disinfector performance standards creates compliance complexity and additional validation cost for multinational hospital networks managing reprocessing protocols across US, European, and Asia Pacific facilities, complicating centralised reprocessing protocol management and adding compliance management overhead above single-jurisdiction hospital systems. These factors substantially limit endoscope sterilization market growth over the forecast period.

Based on product, the global endoscope sterilization market is segmented into automated endoscope reprocessors, high-level disinfectants and chemistries, liquid chemical sterilants, and endoscope tracking and sterility assurance systems. Automated endoscope reprocessors hold the largest revenue share at approximately 42% of 2025 market revenue, processing flexible endoscopes through complete validated disinfection or sterilization cycles within 20 to 35 minutes with documented cycle parameters, chemical concentration, water quality, and scope serial number for AAMI and ASGE compliance. Liquid chemical sterilant systems are expected to register the fastest revenue growth rate in the global endoscope sterilization market over the forecast period, driven by FDA duodenoscope guidance and hospital adoption of STERIS SYSTEM 1E peracetic acid sterilization for duodenoscopes and urological scopes where HLD alone no longer satisfies validated protocol requirements for immunocompromised patient endoscopy programmes.

Based on regional analysis, the endoscope sterilization market in North America accounted for largest revenue share in 2025. The United States drives the regional position through Joint Commission 2024 revised HLD cycle tracking standards, FDA endoscope-specific reprocessing guidance creating duodenoscope compliance requirements that exceed general ISO 15883 standards, and STERIS plc's US-dominant commercial position in AER systems and endoscope sterilization chemistries. STERIS reported US revenues of USD 3.75 Billion in fiscal 2024 per its 10-K, with the Healthcare segment US operations including endoscope reprocessing products generating the majority of Healthcare consumable and service revenue. Custom Ultrasonics' September 2024 FDA manufacturing clearance restored System 83 Plus AER supply to US hospital endoscopy departments, contributing a competitive alternative to STERIS AER procurement for non-duodenoscope endoscopy accounts.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and Scandinavia represent the four largest national endoscope sterilization markets. The SteelcoBelimed JV June 2024 creates a European CSSD platform competing with STERIS on portfolio completeness in European public hospital tenders. NHS England's GBP 4.1 billion endoscopy infrastructure programme is driving AER procurement at NHS trust endoscopy units, with Belimed posting 7.3% organic hospital-segment growth in Q3 2024. HOYA Wassenburg Medical integration creates an integrated Pentax endoscope plus Wassenburg AER reprocessing system offering for European hospital procurement committees. The ongoing Iran-US sanctions and disruption to Strait of Hormuz supply chains affect glutaraldehyde and OPA chemical precursor supply chains for European HLD product manufacturers, maintaining elevated input costs that favour the competitive cost positioning of peracetic acid and plasma-based alternative chemistries.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, South Korea, and Australia represent the four largest national endoscope sterilization markets. HOYA Wassenburg Medical acquisition in November 2023 consolidates a Netherlands-based AER manufacturer with HOYA Pentax Medical flexible endoscope division to create an integrated scope-and-reprocessing-system offering across HOYA Asia Pacific commercial markets. Japan's Ministry of Health, Labour and Welfare guidelines specifying AER use as the preferred GI endoscope reprocessing method at Japanese hospital and endoscopy clinic settings sustain Japan's AER chemistry consumable pull-through revenue. China's National Health Commission 2024 infection control directives mandating standardised endoscope reprocessing at the estimated 24,000 licensed endoscopy centres create a regulatory compliance driver for AER adoption at mid-tier provincial hospital endoscopy departments.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endoscope sterilization markets. Brazil's ANVISA ISO 15883 harmonisation in 2024 creates compliance pressure for Brazilian hospital CSSDs to upgrade toward validated automated washer-disinfector systems and standardised HLD chemistries, and the indirect effects of Iran-US sanctions on South American freight routes have maintained elevated import costs for sterilization chemistry components entering Brazilian and Mexican distribution networks through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC markets. Saudi Vision 2030 healthcare infrastructure investment programmes have driven endoscopy suite expansion at national hospital networks including King Faisal Specialist Hospital and Research Centre, creating new AER and HLD chemistry procurement demand at facilities scaling up endoscopic procedure capacity to serve growing patient populations.